Piper Sandler Boosts Zoetis (NYSE:ZTS) Price Target to $210.00

Zoetis (NYSE:ZTS) had its target price upped by analysts at Piper Sandler from $195.00 to $210.00 in a report released on Wednesday, Benzinga reports. The firm presently has an “overweight” rating on the stock. Piper Sandler’s price objective indicates a potential upside of 14.26% from the stock’s current price.

Several other analysts have also recently commented on the company. The Goldman Sachs Group reduced their target price on Zoetis from $223.00 to $196.00 and set a “buy” rating on the stock in a report on Monday, May 6th. HSBC lowered their price objective on shares of Zoetis from $230.00 to $225.00 and set a “buy” rating for the company in a research note on Wednesday, May 8th. Barclays reduced their price target on shares of Zoetis from $260.00 to $230.00 and set an “overweight” rating for the company in a report on Tuesday, April 23rd. Stifel Nicolaus raised their price objective on Zoetis from $180.00 to $200.00 and gave the company a “buy” rating in a research note on Monday, August 5th. Finally, Argus upgraded Zoetis to a “strong-buy” rating in a report on Friday, August 9th. Nine investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Buy” and a consensus price target of $217.11.

Zoetis Price Performance

NYSE ZTS traded down $4.59 on Wednesday, hitting $183.79. 451,674 shares of the company’s stock were exchanged, compared to its average volume of 2,761,129. The company has a current ratio of 3.45, a quick ratio of 2.09 and a debt-to-equity ratio of 1.32. The stock has a market cap of $83.86 billion, a price-to-earnings ratio of 35.45, a P/E/G ratio of 2.84 and a beta of 0.86. Zoetis has a 52 week low of $144.80 and a 52 week high of $201.92. The stock has a 50-day moving average of $177.34 and a 200-day moving average of $175.26.

Zoetis (NYSE:ZTS) last released its quarterly earnings data on Tuesday, August 6th. The company reported $1.56 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.49 by $0.07. The business had revenue of $2.36 billion during the quarter, compared to analysts’ expectations of $2.31 billion. Zoetis had a net margin of 26.29% and a return on equity of 50.67%. The firm’s quarterly revenue was up 8.3% compared to the same quarter last year. During the same period in the prior year, the company earned $1.41 EPS. Analysts expect that Zoetis will post 5.84 earnings per share for the current year.

Institutional Investors Weigh In On Zoetis

Several large investors have recently added to or reduced their stakes in ZTS. Private Wealth Management Group LLC bought a new position in shares of Zoetis during the fourth quarter valued at about $33,000. Webster Bank N. A. lifted its position in Zoetis by 89.1% during the 1st quarter. Webster Bank N. A. now owns 174 shares of the company’s stock valued at $29,000 after acquiring an additional 82 shares during the period. Gladius Capital Management LP purchased a new stake in Zoetis in the fourth quarter worth about $40,000. Neo Ivy Capital Management bought a new position in shares of Zoetis during the fourth quarter valued at approximately $40,000. Finally, EdgeRock Capital LLC bought a new stake in shares of Zoetis in the 4th quarter worth approximately $45,000. Institutional investors own 92.80% of the company’s stock.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.